P18.19.A EVOLVING STANDARDS: THE INTEGRATION OF NEW THERAPIES INTO NEUROONCOLOGY GUIDELINES
Abstract BACKGROUND In the swiftly progressing domain of neurooncology, continuously updated clinical guidelines are essential to integrate emerging therapeutic developments effectively. This study investigates the perspectives and challenges faced by neurooncology professionals regarding these guid...
Gespeichert in:
Veröffentlicht in: | Neuro-oncology (Charlottesville, Va.) Va.), 2024-10, Vol.26 (Supplement_5), p.v100-v100 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Abstract
BACKGROUND
In the swiftly progressing domain of neurooncology, continuously updated clinical guidelines are essential to integrate emerging therapeutic developments effectively. This study investigates the perspectives and challenges faced by neurooncology professionals regarding these guidelines, with an emphasis on their responsiveness to innovative treatments such as Tumor Treating Fields (TTFields).
MATERIAL AND METHODS
An electronic survey was distributed via the mailing list of the German Neuro-Oncological Working Group, encompassing demographic queries, attitudes towards clinical guidelines, and the assimilation of novel therapies like TTFields. The survey featured Likert-scale items, direct questions concerning the utility and adaptability of guidelines, and specific inquiries regarding the incorporation of TTFields into guidelines. Statistical validation was performed using chi-squared tests, Pearson’s correlations, and Fisher’s exact test.
RESULTS
Out of 87 valid responses, primarily from neurosurgeons (66.7%), a substantial majority (81.6%) affirmed that guidelines enhance the quality of treatment. Nevertheless, 32.2% expressed that these guidelines limit therapeutic freedom. With regard to TTFields, 78.2% were aware of its exclusion from the current DGN glioblastoma guidelines. Analysis indicated a positive correlation between the perception that guidelines enhance treatment quality and the advocacy for their regular revision. The survey also exposed variations in guideline perceptions across different demographic groups, illustrating diverse attitudes towards their utility and progressive adaptation.
CONCLUSION
Clinical guidelines in neurooncology are vital but must be frequently revised to accommodate the latest therapeutic advancements. The findings underscore the necessity for guidelines to adapt dynamically, maintaining their validity and applicability in clinical practice. This study highlights the critical balance between adhering to evidence-based standards and incorporating timely updates, particularly with the integration of innovative treatments such as TTFields. |
---|---|
ISSN: | 1522-8517 1523-5866 |
DOI: | 10.1093/neuonc/noae144.335 |